Please assess the completion status of the following clinical trial:

Trial Title: Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed tumor for which no potential curative therapy exists (e.g., surgery, radiotherapy, or systemic chemotherapy)~  * The following tumor types are eligible:~    * Cutaneous nodular metastatic breast carcinoma lesion with loco-regional cutaneous, soft tissue, or chest wall involvement~      * No chest wall recurrence without prior radiotherapy~     * Other metastatic sites allowed provided patient is concurrently receiving hormonal therapy or trastuzumab (Herceptin) of at least 4 weeks duration~   * Cutaneous or superficial subcutaneous nodular metastatic head and neck lesion~   * Cutaneous nodular Kaposi's sarcoma lesion~   * Stage IA-IIB or IVA cutaneous T-cell lymphoma (CTCL)~      * CTCL patches, plaques, or tumors with a surface area of up to 25 cm\^2 if other areas of involved skin are blocked from therapy~   * Squamous cell or basal cell carcinoma of the skin that is not eligible for standard therapy (e.g., cryosurgery, radiotherapy, electrodesiccation and curettage, or excision)~   * Cutaneous and subcutaneous metastasis from any solid tumor (e.g., thoracic, gastrointestinal, or genitourinary cancers or sarcomas)~* Bidimensionally measurable disease~  * No more than 2 lesions may be treated~* No single area greater than 36 cm\^2 may be treated (maximum of 25 cm\^2 tumor mass with a 1 cm margin)~* Tumor treatable by surface (non-contact) light illumination~* Skin type I-III~* No tumors of the eyelids~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Sex:~* Male or female~Menopausal status:~* Not specified~Performance status:~* ECOG 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3~* Hemoglobin at least 9 g/dL~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.5 mg/dL~* AST/ALT no greater than 2 times upper limit of normal (ULN)~* Alkaline phosphatase no greater than 2 times ULN~* No history of hepatic cirrhosis~* No hepatic disease requiring therapy~Renal:~* Creatinine no greater than 2.0 mg/dL OR~* Creatinine clearance at least 50 mL/min~* No renal disease requiring therapy~Cardiovascular:~* No myocardial infarction within the past 6 months~* No significant congestive heart failure requiring therapy~* No peripheral vascular disease~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Antinuclear antibody negative~* No sepsis~* No prior allergic or hypersensitivity reaction to paclitaxel vehicle~* No known photosensitivity diseases such as porphyria, systemic lupus erythematosus, xeroderma pigmentosum, or polymorphous light eruption~* No symptomatic collagen vascular disease~* Insulin-dependent or adult-onset diabetes mellitus allowed provided there are no lower extremity lesions~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Disease Characteristics~* At least 4 weeks since prior immunotherapy~* No concurrent immunotherapy~Chemotherapy:~* See Disease Characteristics~* At least 4 weeks since prior systemic chemotherapy~* No concurrent chemotherapy~Endocrine therapy:~* See Disease Characteristics~* No concurrent corticosteroids~Radiotherapy:~* See Disease Characteristics~* More than 4 weeks since prior radiotherapy~* More than 4 weeks since prior ultraviolet B light therapy or psoralen-ultraviolet light therapy to non-study lesions/areas~* No concurrent radiotherapy~Surgery:~* See Disease Characteristics~Other:~* At least 5 days since prior warfarin~* At least 4 weeks since prior investigational drugs~* At least 4 weeks since prior local therapy to study lesions~* At least 6 months since prior photodynamic therapy~* No concurrent aspirin, aspirin-containing medications, or non-steroidal anti-inflammatory drugs (e.g., ibuprofen, indomethacin, or cyclo-oxygenase \[COX\]-1 and COX-2 inhibitors)~* No other concurrent photosensitizing medications such as tetracyclines, psoralens, nalidixic acid, griseofulvin, sulfa drugs, hydrochlorothiazide, furosemide, phenothiazines, or amiodarone~* No concurrent therapeutic dosages of warfarin (non-therapeutic dosages allowed)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues